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Abstract Cancer-related symptoms such cachexia and pain
are subjects of a proliferation of assessment tools, diagnos-
tic criteria, and systems for staging, which are notably
disparate, and lack agreement on the variables to be
measured. Teams of experts have worked diligently to
develop consensus definitions of the terms cachexia and
cancer cachexia, and these efforts provide the basis to
develop agreement upon the measurements and tools that
are applicable to the diagnosis and staging of cancer
cachexia.
Cachexia has lacked a universally accepted definition.
Descriptions of cachexia in much of the early literature
invariably presented it as a multidimensional condition or
syndrome, encompassing a constellation of contributing
factors (i.e., weight loss, anorexia, chemosensory distor-
tion, early satiety, inflammation, hypermetabolism) and
outcomes (i.e., asthenia, dyspnea, anemia, psychosocial
distress, dependency upon others, treatment toxicity,
death). These descriptive terms captured the context and
conveyed a sense of the suffering, but did not constitute a
definition.
The teams of experts have worked diligently to develop
consensus definitions of the terms cachexia and cancer
cachexia [1–3]. A series of core concepts are consistently
included in these definitions: (a) Cachexia is characterized
by progressive depletion of body reserves (loss of weight,
lean tissue, and fat mass). (b) Cachexia is associated with
reduced food intake and altered metabolism, in varying
proportions. (c) Reduced food intake is due to anorexia as
well as a series of disease- and treatment-related symptoms
which impact intake. (d) Changes in metabolism are also a
defining feature of cachexia, and include tumor metabo-
lism, inflammation, increased proteolysis and lipolysis, and
the presence of comorbid conditions further exacerbate
these changes. (e) Cancer cachexia develops over time,
starting with early and subtle manifestations, progressing
eventually to an advanced stage. (f) Loss of physical
function, quality of life, enhanced treatment toxicity, and
shortened survival are regarded as key consequences of
cachexia.
With the advent of a definition for cancer cachexia, it is
possible to proceed to the next step—diagnostic criteria and
staging. Both of these tasks imply the assessment and the
quantification of the multiple features mentioned above.
Crucial to this enterprise is a definition of the variables that
should be measured, the appropriate tools to measure them
with, and appropriate statistical methods to evaluate the
data.
These quantified variables are necessarily stratified in
the levels of screening, full clinical assessment, and
research (investigational assessment). The first level
(screening) encompasses a brief overall assessment that
has widespread clinical utility and can be used in places not
necessarily equipped with all facilities and expertise for the
full clinical and investigational assessments. The elements
of the screening assessment will have utility as part of a
minimum essential data set which can be combined across
sites to develop demographic profiles of the problem. It will
be possible to develop high quality international data sets
demonstrating the key demographics of cachexia features,
on a worldwide basis, including all types of settings where
cancer patients are to be found.
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the assessment of cancer cachexia (i.e., [4–7]), and the new
ones are being proposed (i.e., Busquets et al., in this issue).
There is also a long list of potential in depth and
investigational assessments to be considered. However,
the efforts to build assessment tools, unless coordinated
and based on consensus processes, risk producing a
disparate set of instruments, forming data sets that are
incoherent, and most importantly, will not be amenable to
meta-analysis owing to a lack of agreement on even the
most basic of parameters to be evaluated.
An example illustrating this point is the lack of a
standardized method for recording weight history. Cancer
cachexia is defined by the presence of involuntary weight
loss, and while that may seem simply quantified, there is
great disparity in the way that this is done. Weight loss
(a continuous variable) is graded with varying cut points
of 2%, 5%, 10%, 12%, 15%, and 20%. Time frame of
t h ew e i g h tl o s s ,1 ,3 ,o r6m o n t h so rs i n c ep r e m o r b i d
state (not usually clearly defined), is variously reported.
While the intensity of the loss (rate of loss per unit time)
is viewed as crucial by experts in clinical nutrition, the
time frame of weight loss is frequently not specified. The
current crop of mismatched information with arbitrarily
chosen cut points need to be replaced with well-powered
representative samples, with an agreed set of measures
related to body weight taken over a known time frame,
coupled with rigorous statistical approaches (receiver
operating curves, optimal stratification) to detect the cut
points that are relevant to cancer-specific outcomes.
Beyond the simple assessment of body weight is the
daunting issue of defining the crucial measures related to all
of the other dimensions of cachexia, including erosion of
the lean body mass, food intake, the symptoms impairing
dietary intake metabolic alterations as well as physical
functioning and other outcomes. Measures in each of these
domains will require validation. The cost, availability, and
invasiveness of each measure will define whether they can
be used in screening, full assessment, or investigational
(research) studies only. Availability is not a trivial issue,
a n dF e a r o ne ta l .[ 1] suggest that any of anthropometry,
computed tomography, dual energy X-ray, or bioelectrical
impedance could be used to define lean tissue/muscle
depletion (≤5th percentile compared to healthy adults).
This approach sets a standard, but allows for the
assessment to be done with the tools at hand, in any
setting. The metabolic abnormalities associated with
cancer cachexia will be the most difficult domain in which
to resolve the key measures, as essentially none are
validated and many are costly, invasive, or of limited
availability. The first and most widely agreed biomarker of
metabolic abnormality is C reactive protein, and there is a
need for investigation and validation of the additional
assessments. It seems premature [8] to propose that plasma
levels of interleukins-6 and 2, blood triglyceride analyses,
glucose tolerance, and skin hypersensitivity test are ready
to be incorporated in the first-line assessments of cancer
cachexia.
We certainly need validated tools, and this may be
best accomplished from working off the platform of a
robust conceptual framework and by collaborating
closely to build the diagnostic criteria and develop
staging. These issues are not unique to cancer cachexia.
I would point to the ~50 different tools for assessment
of cancer pain in the literature [9]. This proliferation of
cancer pain assessments is not useful, and now efforts are
ongoing by consensus groups to reduce this to a
parsimonious number of more widely accepted tools [9,
10]. My hope is that the cachexia community will work
together to limit the duration of its own transit through the
stage in which, like the parable of the Tower of Babel,o u r
efforts are diminished by the lack of a common language.
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